摘要
免疫治疗联合化疗已经成为晚期食管鳞癌患者的一线治疗。然而,整体人群有效率和获益率低等问题仍然存在。近年来,许多免疫检查点抑制剂以及靶向药物纷纷问世,一些新的治疗模式的探索,包括免疫治疗联合放化疗,免疫治疗联合靶向治疗,以及双重免疫检查点抑制剂联合治疗等都取得了较大的研究进展。本文将相关重要研究简要总结,希望为食管癌的治疗带来更多启示。
Immunotherapy combined with chemotherapy has become the first⁃line treatment for advanced esophageal squa⁃mous cell carcinoma patients.However,issues such as low efficiency in overall population and profitability still exist.In re⁃cent years,many immune checkpoint inhibitors and targeted drugs have emerged,and significant research progress has been made in exploring new treatment modes,including immunotherapy combined with chemoradiotherapy,immunotherapy com⁃bined with targeted therapy,and dual immune checkpoint inhibitor therapy.This article provides a brief summary of relevant important research,hoping to provide new insights for the treatment of esophageal cancer.
作者
邢思远
孟祥瑞
单争争
王峰
Xing Siyuan;Meng Xiangrui;Shan Zhengzheng;Wang Feng(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,China)
出处
《肿瘤预防与治疗》
2024年第4期348-357,共10页
Journal of Cancer Control And Treatment
基金
河南省自然科学基金面上项目(编号:222300420557)
希思科-罗氏肿瘤研究基金(2019年度)(编号:Y-2019Roche-092)
河南省科技攻关项目(编号:232102310343)
河南省科技攻关项目(编号:222102310694)。
关键词
晚期食管癌
免疫治疗
靶向治疗
联合治疗
抗血管生成药物
Advanced esophageal cancer
Immunotherapy
Targeted therapy
Combination therapy
Antiangiogenic drug
